• Read our press releases

    Some of our recent press releases are highlighted below. To view all of our past press releases, or to view them in Swedish, please visit our Global or Swedish Newsrooms using the link buttons at the bottom of this page.

    September 29, 2020 – Genosity and Olink Proteomics announce strategic collaboration

    Genosity Inc, and Olink Proteomics AB announced today that they have entered into a strategic services and collaboration agreement within the United States. This will allow Olink to further expand its innovative protein biomarker discovery services for the U.S. market, while enabling Genosity to add high throughput proteomics to its repertoire of available technologies.

    View the full press release>

    September 18, 2020 – Data publicly released to the global research community from the largest proteomics study on COVID-19 – a collaboration between Massachusetts General Hospital and Olink

    Olink is proud and delighted to announce its contribution to one of the largest longitudinal COVID-19 proteomics studies to date, together with the prestigious Massachusetts General Hospital (MGH). Working with the outstanding research team from MGH, protein measurements and associated clinical data have been made available via the Olink company website.

    View the full press release>

    July 8, 2020 – WuXi NextCODE and Olink Proteomics announce strategic cooperation

    With this new and important collaboration, customers in China will have access to run Olink fee for service projects in a similar way that customers have in other parts of the world. It will also mean that WuXi NextCODE will further improve their capability for high-throughput multi-omics research, based on genomics, transcriptomics and proteomics.
    View the full press release>

    June 3, 2020 – Proteomics on NGS: The launch of Olink Explore 1536 will be a game changer

    Olink Proteomics announces the launch of Olink® Explore 1536, combining the company’s unique proximity extension assay (PEA) high-multiplex technology with next-generation sequencing (NGS) readout on the Illumina® NovaSeq platform.
    View the full press release>

    May 12, 2020 – Olink acquires Agrisera AB

    Olink Proteomics AB announce the strategic acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays. The acquisition is an important milestone for Olink in its aim to rapidly increase the number of assays available for its unique PEA technology which allows for an unparalleled multiplexing with rigorous validation for each assay.
    View the full press release>

    March 12, 2019 – Summa Equity acquires Olink Proteomics

    Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to continue building its base of investments within life science.
    View the full press release>

    December 13, 2018 – Olink Proteomics announces a new oncology-focused biomarker panel that expands its protein library to over 1100 high-quality assays

    Olink Proteomics today announced the launch of Olink® ONCOLOGY III, a new oncology-focused biomarker panel that complements and expands on Olink’s growing portfolio of thoroughly validated assays, extending the power of the Olink platform for discovery-scale applications to 1164 different human protein biomarkers.
    View the full press release>

    August 31, 2018 –  Olink Proteomics announces a new biomarker panel that expands its protein library to over 1000 high-quality assays

    Olink Proteomics today announced the launch of Olink® NEURO EXPLORATORY, a new biomarker panel that complements and expands on Olink’s ever-growing portfolio of high quality protein assays. The new panel extends the power of the Olink platform for discovery-scale application to 1072 different protein biomarkers.
    View the full press release>>

    December 14, 2017 – Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies

    Olink Proteomics today announced the launch of Olink® MOUSE EXPLORATORY, offering 92 high-quality assays to measure mouse proteins. The panel is based on the same, well-established Proximity Extension Assay (PEA) technology behind Olink’s portfolio of high-multiplex panels for human protein biomarker discovery, and has been developed to the same high standards of validation and quality control.
    View the full press release >>

    February 16, 2017 – Olink Proteomics announces the availability of three additional biomarker panels focused on key biological processes with broad clinical relevance

    Olink Proteomics today announced the launch of three new precision proteomics panels, further expanding its rapidly growing library of high quality human protein biomarker assays to almost 1000. The focus areas for these three new panels are Cardiometabolic, Cell Regulation and Development.
    View the full press release >>

    November 29, 2016 – Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome

    Olink Proteomics today announced the launch of three new precision proteomics panels, significantly expanding its library of high quality human protein biomarker assays, from 460 to over 700. This series of new panels is designed to enable scientists to extend their discovery capabilities for studying the plasma proteome by casting a broader net, thereby maximizing their chances of identifying clinically relevant protein signatures.
    View the full press release >>

    September 21, 2016 – Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology.

    Olink Proteomics today announced that Proseek®Multiplex Immuno-Onc I, the broadest protein biomarker panel targeting critical biological process related to immunotherapy, is now available for immediate delivery. Developed to meet a clearly expressed need from customers, the panel is designed to help companies, scientists and clinicians working with immunotherapy-based approaches to treat cancer.
    View the full press release >>

    May 31, 2016 –  Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

    Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.
    View the full press release >>

    April 12, 2016 – A new company organization to meet our future ambitions

    Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

    Olink Proteomics will continue to expand and develop the Proseek® Multiplex product line for targeted human protein biomarker discovery, while Olink Bioscience will focus on developing and commercializing the many additional technologies held within Olink’s extensive and growing, diverse IP portfolio.
    View the full Press Release >>

     

    January 27, 2016 – Olink introduces a new precision proteomics solution for neurology

    Olink today launched Proseek® Multiplex Neurology I, a new human protein biomarker panel that targets research into neurobiology and neurological diseases. This latest development of the Proseek platform expands the library of unique biomarkers available to over 440 in total, and opens up Olink’s innovative precision proteomics offering into a new and exciting field.
    View the full press release >>